World Library  
Flag as Inappropriate
Email this Article
 

BioLineRx

BioLineRx Ltd.
Type Public
Traded as NASDAQ: BLRX
TASE: BLRX
Industry Biotechnology
Founded 2003 (2003)
Headquarters Jerusalem, Israel
Key people Kinneret Savitsky (CEO)
Services Drug development
Website .com.biolinerxwww
Footnotes / references
[1]
BioLineRX office in Har Hotzvim Technology Park, Jerusalem

BioLineRx (Hebrew: ביוליין אר אקס‎), or BioLine, is a publicly traded drug development company that seeks to discover compounds for disease treatment and develop them into commercializable drugs. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.

Contents

  • Operations 1
    • Pipeline 1.1
    • Business model 1.2
  • Corporate history 2
    • Management 2.1
  • See also 3
  • References 4
  • External links 5

Operations

BioLineRx is a drug development company that seeks to discover compounds with potential to treat a variety of diseases, including cancer, schizophrenia and cardiac deterioration. When promising compounds are discovered, BioLine leads them through preclinical trials and engages other companies to advance the compounds' development into commercializable drugs.[2] The company entered into its first major commercialization agreement in 2009 when it partnered with Ikaria Holdings Inc. to develop its BL-1040 compound.[3] In 2010 BioLine entered into a commercialization agreement with Cypress Bioscience Inc. for development of its BL-1020 compound. The agreement with Cypress was canceled in 2011 when the company was taken over by Ramius LLC.[4]

Pipeline

Below is a partial list of drug compounds in various stages of development by BioLineRx. Unless indicated otherwise, they have not obtained regulatory approval in relation to the diseases cited.

Business model

BioLine's business model consists of three stages. In the first stage, called the bench stage, the potential drug candidate is evaluated "from both scientific and marketing perspectives." In the second stage, called the bedside stage, BioLine accompanies the drug through early clinical trials. In the third stage, the partner stage, BioLine enters into strategic partnership with a pharmaceutical company to see the drug through its advanced clinical trials and bring it to the market.[12]

Corporate history

BioLineRx was established in 2003 as a joint venture of Teva, Hadasit Bio-Holdings, the Jerusalem Development Authority, Yehuda Zisapel, and other investors.[13] It executed an initial public offering on the Tel Aviv Stock Exchange in February 2007, raising NIS 211 million ($50 million) – the TASE's largest biotech IPO until that time.[14][15] In August 2011 BioLine's ADRs began trading on the NASDAQ Capital Market.[16] In January 2012, BioLineRx announced a deal with Genoscience, a French pharmaceutical company to jointly develop and market the BL-8020 compound, as a treatment for Hepatitis C.[17]

Management

Morris Laster, Downstate Medical Center (M.D.) and SUNY Albany (B.Sc.) alumnus, was CEO of BioLineRx until 2009. He was replaced by Kinneret Savitsky, alumnus of Tel Aviv University (Master's and Ph.D.) and the Hebrew University of Jerusalem (B.Sc.), early in 2010.[18]

See also

References

  1. ^ "BLRX Profile: BioLineRx Ltd. Stock".  
  2. ^ Brinn, David (3 June 2007). "BioLineRx - Israel's biotech supermarket". Israel21c. Retrieved 28 November 2011. 
  3. ^ Habib-Valdhorn, Shiri (28 April 2010). "BiolineRX earns $10m milestone payment".  
  4. ^ Weinreb, Gali (11 May 2011). "BiolineRX and Cypress cancel schizophrenia drug agreement".  
  5. ^ "Israeli co to hold clinical trial for treatment of Schizophrenia in India".  
  6. ^ "BioLineRx Announces Positive Preliminary Results from Phase I Clinical Trial of BL-1021 for Neuropathic Pain".  
  7. ^ "Bioline looks to heart attack treatment clinical trial".  
  8. ^ "US company buys exclusive license for Israeli heart attack drug for $285 million". Israel21c. 8 July 2009. Retrieved 28 November 2011. 
  9. ^ Wrobel, Sharon (15 September 2011). "Bioline RX Gets European Device Confirmation for Bl-5010 Drug".  
  10. ^ "BioLineRx has acquired the rights to compound BL-7040 from Yissum and Prof. Soreq".  
  11. ^ "BioLineRx signs pact with Genoscience & RFS Pharma to develop and commercialize BL-8030 to treat hepatitis C". Pharmabiz.com ( 
  12. ^ "BioLineRx – Overview". BioLineRx. 2010. Retrieved 28 November 2011. 
  13. ^ Grayeff, Yigal (13 January 2005). "BioLineRx signs 3 deals to develop drugs".  
  14. ^ Cohen, Omri (7 February 2007). "Biotech comes of age: Bioline floats at half-billion shekel market cap".  
  15. ^ Rheinheimer, Laura (8 February 2007). "BioLineRx raises $50m. in TASE's largest biomedical IPO".  
  16. ^ "BioLineRx ADRs Begin Trading on NASDAQ".  
  17. ^ Achillion, BioLineRx, J&J Snack, Rubicon: U.S. Equity Movers
  18. ^ http://investing.businessweek.com/research/stocks/people/person.asp?personId=8011457&ticker=BLRX:IT&previousCapId=3274115&previousTitle=EVOGENE%20LTD

External links

  • BioJerusalem
  • Jerusalem Development Authority
  • Office of the Chief Scientist of Israel
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from World Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.